<DOC>
	<DOCNO>NCT02679040</DOCNO>
	<brief_summary>At present , widely admit propose immediate mammary reconstruction adjuvant radiotherapy indicate significant change cosmetic result ( profit ) whatever technique reconstruction adopt . This true reconstruction prosthesis prothetic die risk hull ( shell ) . Teams propose immediate mammary reconstruction expand ( carrier ) patient carcinoma infiltrate , sometimes locally move forward . For patient , bring back ( report ) increase risk local remote relapse . Two study estimate afterward feasibility mastectomy immediate mammary reconstruction close chemotherapy radiotherapy . The rate morbidity judge acceptable . The rate local second offense ( recurrence ) similar patient benefit classic therapeutic plan . During study ( M-RIC ) , show inversion therapeutic sequence possible prescribe chemotherapy radiotherapy immediate mammary reconstruction , morbidity acceptable . It acquire chemotherapy néoadjuvant equivalent post-operative chemotherapy regard global survival . On hand , rate histological answer , accord subgroup , different . This rate vary 9 % tumor RH + , negative Her2 45 % tumor RH- , Her2 expression . There 33 % RH + , Her2 + 35 % triple-negative . The purpose investigator study estimate rate histological response inversion therapeutic sequence make sure oncologic safety ( security ) , particular molecular subgroup , consider heterogeneousness result ( profit ) chemotherapy néoadjuvant . Sataloff Chevallier Classifications reference use , investigator also use Symmans classification addition . The rate local metastatic second offense ( recurrence ) also estimate .</brief_summary>
	<brief_title>Rate Histological Response After Mastectomy Mammary Reconstruction Close Neo-adjuvant Chemotherapy Radiotherapy</brief_title>
	<detailed_description />
	<criteria>Age &gt; 18 year , Infiltrating carcinoma , Neoadjuvant chemotherapy indication , Radiotherapy indication , 0 1 score Performance status ( WHO ) , Signed informed consent , Affiliation Social Security System Lobular carcinoma , `` Luminal A '' Tumor ( RH+ Her2 negative grade I , tumor RH+ Her2 negative grade II Ki67 &lt; 20 % ) , Attempt first conservative treatment , Metastatic breast cancer , Inflammatory carcinoma , History homolateral controlateral mammary carcinoma , Progression disease ( despite neoadjuvant chemotherapy ) , Contraindications immediate mammary reconstruction scrap big dorsal ( comorbidity ) , Any psychological , familial , sociological geographical conditionpotentially hamper compliance study protocol followup schedule , Patients deprive liberty place authority tutor .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>